NDAC Member Resigns Over Plan B; Other Committees Discuss Departures
This article was originally published in The Tan Sheet
Executive Summary
Former Nonprescription Drugs Advisory Committee member Frank Davidoff, MD, no longer plans to advise other committee members to resign from their duties in protest of the agency's handling of the Barr Labs' Plan B switch application
You may also be interested in...
FDAer Resigns Over Plan B; Senators Seek Results Of GAO Investigation
FDA Office of Women's Health Director Susan Wood is resigning over the agency's handling of Barr Labs' application to switch its Plan B emergency contraceptive over-the-counter
FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC